India Pharma Outlook Team | Monday, 11 May 2026
Abbott has launched its TriClip TEER system in India, bringing a new minimally invasive treatment option for patients suffering from tricuspid regurgitation (TR), a serious heart valve disorder caused by a leaking tricuspid valve.
The launch marks a major step in expanding advanced structural heart therapies in the country, especially for patients considered high-risk or unsuitable for open-heart surgery.
The TriClip TEER system is delivered through a vein in the leg and works by clipping together sections of the damaged tricuspid valve leaflets to help restore proper blood flow. The procedure avoids the need for open-heart surgery and generally allows patients to leave the hospital within a day after treatment.
Also Read: Transforming API & Pharma Manufacturing with Next-Gen EHS Technologies
Abbott said the technology is based on its MitraClip platform, which is already used globally for mitral valve repair. However, TriClip has a specialized delivery system designed specifically for the right side of the heart, where the tricuspid valve is located.
Tricuspid regurgitation occurs when the valve fails to close completely, causing blood to flow backward inside the heart. The condition can trigger symptoms including fatigue, shortness of breath, atrial fibrillation, and heart failure if left untreated.
According to Abbott, awareness of TR is growing in India, particularly among elderly patients and people living with rheumatic heart disease, pulmonary hypertension, or other cardiac conditions.
Sudheer Mirajkar, Country Manager for Abbott’s Structural Heart business in India, said the introduction of TriClip increases treatment choices for patients who cannot undergo surgery and may improve both quality of life and long-term clinical outcomes.
.jpg)
.jpg)
